Phathom Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US71722W1071

SecurityPHAT / Phathom Pharmaceuticals, Inc.
InstitutionCreative Planning
Latest Disclosed Ownership70,193 shares
Latest Disclosed Value $ 779,844
Creative Planning reports 13.09% decrease in ownership of PHAT / Phathom Pharmaceuticals, Inc.

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 70,193 shares of Phathom Pharmaceuticals, Inc. (US:PHAT) valued at $779,844 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 80,766 shares of Phathom Pharmaceuticals, Inc.. This represents a change in shares of -13.09% during the quarter. The current value of the position is $708,247 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 70,193 -10,573 -13.09 780 -41.82 0.0005
2026-02-17 2025-12-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 80,766 2,708 3.47 1,340 45.86 0.0010
2025-11-14 2025-09-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 78,058 20,794 36.31 919 67.21 0.0007
2025-08-08 2025-06-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 57,264 -2,673 -4.46 549 46.40 0.0005
2025-05-15 2025-03-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 59,937 36,694 157.87 376 99.47 0.0004
2025-02-14 2024-12-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 23,243 -10,641 -31.40 189 -69.28 0.0002
2024-10-11 2024-09-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 33,884 6,933 25.72 613 120.94 0.0006
2024-08-15 2024-06-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 26,951 -5,151 -16.05 278 -18.53 0.0003
2024-05-13 2024-03-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 32,102 10,750 50.35 341 75.26 0.0004
2024-02-14 2023-12-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 21,352 877 4.28 195 -8.49 0.0004
2023-11-16 2023-09-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 20,475 0 0.00 212 -27.65 0.0003
2023-07-21 2023-06-30 13F PHATHOM PHARMACEUTICALS COM 71722W107 20,475 475 2.38 293 106.34 0.0004
2023-05-15 2023-03-31 13F PHATHOM PHARMACEUTICALS COM 71722W107 20,000 20,000 143 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.